Document Classification

Section Type: RESULTS

Text: 383 (64 %) of 596 patients taking natalizumab and 117 (39 %) of 301 taking placebo were free of clinical disease activity (absolute difference 25. 4 %, 95 % CI 18. 7-32. 1 %, p < 0. 0001) ; 342 (58 %) of 593 and 42 (14 %) of 296 were free of radiological disease activity (43. 5 %, 37. 9-49. 1 %, p < 0. 0001) ; and 220 (37 %) of 600 and 22 (7 %) of 304 were free of combined activity (29. 5 %, 24. 7-34. 3 %, p < 0. 0001) over 2 years.